Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma

a single-center case series and review of the literature.

Michael Martin, Ravi Vij

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk of arterial events is less well appreciated. We describe 5 unusual arterial thromboses in patients with MM shortly after beginning thalidomide-based therapies. The cases are remarkable for a paucity of risk factors and short latency. We also review the literature on arterial thromboembolic events in patients taking thalidomide. Care should be taken in future trials to document arterial events with both thalidomide and lenalidomide.

Original languageEnglish (US)
Pages (from-to)320-323
Number of pages4
JournalClinical lymphoma & myeloma
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2009

Fingerprint

Thalidomide
Multiple Myeloma
Thrombosis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{0ec935f446524991a7a288476921ab80,
title = "Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.",
abstract = "Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk of arterial events is less well appreciated. We describe 5 unusual arterial thromboses in patients with MM shortly after beginning thalidomide-based therapies. The cases are remarkable for a paucity of risk factors and short latency. We also review the literature on arterial thromboembolic events in patients taking thalidomide. Care should be taken in future trials to document arterial events with both thalidomide and lenalidomide.",
author = "Michael Martin and Ravi Vij",
year = "2009",
month = "1",
day = "1",
doi = "10.3816/CLM.2009.n.063",
language = "English (US)",
volume = "9",
pages = "320--323",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma

T2 - a single-center case series and review of the literature.

AU - Martin, Michael

AU - Vij, Ravi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk of arterial events is less well appreciated. We describe 5 unusual arterial thromboses in patients with MM shortly after beginning thalidomide-based therapies. The cases are remarkable for a paucity of risk factors and short latency. We also review the literature on arterial thromboembolic events in patients taking thalidomide. Care should be taken in future trials to document arterial events with both thalidomide and lenalidomide.

AB - Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk of arterial events is less well appreciated. We describe 5 unusual arterial thromboses in patients with MM shortly after beginning thalidomide-based therapies. The cases are remarkable for a paucity of risk factors and short latency. We also review the literature on arterial thromboembolic events in patients taking thalidomide. Care should be taken in future trials to document arterial events with both thalidomide and lenalidomide.

UR - http://www.scopus.com/inward/record.url?scp=73849116994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849116994&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.063

DO - 10.3816/CLM.2009.n.063

M3 - Article

VL - 9

SP - 320

EP - 323

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -